When do you expect the 2023 FIGO staging for endometrial cancer to become adopted clinically in the US?

Agree with the previous comment. Current adjuvant RT for stage I and II are based on mainly histopathological classification (PORTEC-I/II). However, the recent publication of PORTEC-4a (Horeweg et al., PMID 37487144) for stage I/II showed molecular classification predicts response for stage I/II. Mo...

I think, to some degree, we are already using the new FIGO system to make clinical decisions.

We are not routinely using it at the current time and are unlikely to change until NCCN adopts, which (IMO) will be dependent on prospective data from PORTEC-4a being published. What Dr. @Dr. First Last linked is a retrospective classification of PORTEC-1/2 patients, which, while not technically pro...